Agios Withdraws European Tibsovo AML Submission

Agios has withdrawn its EU marketing authorization application to the European Medicines Agency for Tibsovo (ivosidenib) for the treatment of adults with relapsed or refractory acute myeloid leukemia (AML) featuring an isocitrate dehydrogenase-1 (IDH1) mutation. Source: Drug Industry Daily

Read More

UK Authorizes COVID-19 Human Challenge Trial

The British government has entered into a contract to conduct human challenge trials in which participants will be deliberately infected with COVID-19 to bolster development of a vaccine. Source: Drug Industry Daily

Read More